In The Spotlight

From media giants to exclusive industry publications, Humacyte stays in the news.

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale Going Public via Merger with Alpha Healthcare Acquisition Corp.

February 17, 2021

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

January 12, 2021

Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11

January 10, 2021

Laura Niklason to Speak at Milken Institute Future of Health Summit

December 9, 2020

Humacyte Appoints Founder Laura Niklason MD, PhD as President and Chief Executive Officer

November 20, 2020

New Paper Defines Breakthroughs in Vascular Tissue Engineering

October 9, 2020

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

March 2, 2020

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

April 8, 2019

Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”

March 29, 2019

Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 8, 2019

NC Companies Shine At SEBIO Forum

November 28, 2018

Humacyte Commences Phase II Vascular Trauma Trial

October 25, 2018

Humacyte Appoints Doug Blankenship as Chief Financial Officer

October 8, 2018

U.S. Kidney Patients Help Drive Care Innovation Patient insights Accelerate Research and Development

July 25, 2018

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

June 20, 2018

Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment

June 12, 2018

Humacyte Closes $75 Million Series C Financing

March 9, 2018

Humacyte Awarded $3.4 Million Contract Award from The U.S. Department of Defense

October 2, 2017

Humacyte Receives $14.1 Million Award from California Institute for Regenerative Medicine to Expand Clinical Applications of HUMACYL®

September 29, 2017

Humacyte Receives Award from the Medical Technology Enterprise Consortium

September 27, 2017

Humacyte Completes Patient Enrollment for Phase III Clinical Trial of Human Acellular Vessel

September 7, 2017

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

June 14, 2017

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale, Going Public via Merger with Alpha Healthcare Acquisition Corp.

December 1, 2020

Humacyte’s Bioengineered Blood Vessel Implanted by Clinicians at Walter Reed to Restore Blood Circulation to Retired Military Veteran’s Leg

November, 19, 2020

Bioengineered human blood vessels

October 20, 2020

Humacyte and CNTR Team on MTEC Grant to Study the Evidence on Repair of Vascular Trauma

February, 2020

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

May 27, 2019

First Penn Scholarship Recipient off to Yale

May 23, 2019

Oh, the Places Grads Go

May 22, 2019

Surgeons Perform First Bioengineered Blood Vessel Transplant in Military Patient

May 10, 2019

Bioengineered blood vessels could replace vasculature damaged by renal failure, CVD

April 9, 2019

Artificial blood vessels that come to life could improve medical care. Here’s why

April 4, 2019

TBJ reveals 2019 Life Sciences Awards winners

March 29, 2019

Study finds Humacyte acellular vessels repopulated to create living vessels

March 29, 2019

Scientists Make Blood Vessels From Cadaver Tissues And Bring Them to Life in Patients

March 28, 2019

Lab-grown blood vessels provide hope for dialysis patients

Awards & Acknowledgments

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

Recognized as a Pioneer in Vascular and Lung Engineering and Biomedical Imaging

Vermont Distinguished Academic Achievement Award

Diversity Journal Women Worth Watching

Humacyte’s Sabrina Osborne, Vice President of Human Resources, was named a 2019 winner for Diversity Journal’s women Worth Watching list.

Triangle Business Journal Life Sciences Awards

Humacyte recognized for best late-stage product development company’ category.

Triangle Business Journal

List of Largest Biotech/Pharma Companies in the Triangle

Triangle Business Journal 2018 Innovation Awards

Humacyte President and Chief Executive Officer was selected to Triangle Business Journal’s 2018 Innovation Awards List.

Humacyte was named as a finalist in the Strategic Investment Category to the SEBIO 2018 Awards List

Humacyte was recognized for securing a $150M strategic investment from Fresenius Medical, the world’s largest dialysis company, to commercialize HUMACYL for dialysis applications.

Triangle Business Journal 2018 C-Suite Awards List

Humacyte Chief Regulatory Office Bill Tente was selected to Triangle Business Journal’s 2018 C-Suite List.

Diversity Journal Women’s Worth Watching

Gretchen Smith, Humacyte’s Executive Director, Manufacturing was named a 2018 winner for Diversity Journal’s Women Worth Watching list.

Humacyte Founder Shannon Dahl’s, Ph.D. Named to the 2018 PharmaVoice100 List Awards Finalist

Dr. Dahl was recognized by PharmaVoice for breaking bioengineering ground, with regenerative medicine.

Humacyte’s Theodore Lithgow, Chief Operations Officer, was recognized in the 2017 Best in Biz awards under the Executive of the Year

Medical Design & Outsourcing: Humacyte’s Carrie Cox named to 9 Women Medtech Leaders You Need to Know list

Humacyte Founder Laura Niklason, M.D., Ph.D. Named to the 2017 PharmaVoice100 List Awards Finalist

Dr. Niklason was recognized by PharmaVoice for her contributions to the advancement of regenerative medicine, in creating investigational human acellular vessels.

Humacyte Founder Laura Niklason, M.D., Ph.D. Inducted into the Women in Technology (WITI) Hall of Fame

Dr. Niklason was inducted into the Women in Technology Fall of Fame for her groundbreaking research in regenerative strategies for cardiovascular and lung tissues.

Humacyte’s Heather Prichard, Ph.D., named as a 2017 award winner for Diversity Journal’s Women Worth Watching in STEM

Senior Vice President, Product Development Dr. Heather Prichard was named as a 2017 award winner for Diversity Journal’s Women Worth Watching in STEM in recognition of her work to develop technologies for improving medical treatment for a variety of diseases.

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

Humacyte was selected as a 2017 Technology Pioneer by the World Economic Forum for the potential to significantly impact business and society through new technologies in regenerative medicine.

Humacyte’s Juliana Blum and Jenny Jackson Named to Profiles in Diversity Journal’s 2017 Women Worth Watching List

Dr. Juliana Blum, Co-Founder and Vice-President, Business Operations & Tissue Services and Jenny Jackson, Associate Director of Reimbursement for Humacyte, were recognized to Diversity Journal’s Women Worth Watching in 2017 award for their personal and professional contributions to advancing gender diversity.

Humacyte Founder Dr. Laura Niklason and Humacyte CEO Carrie Cox Named to Becker’s Hospital Review List of 110 Women in Medtech to Know

Humacyte Founder, Dr. Niklason and Humacyte CEO, Carrie Cox were both recognized to Becker’s Hospital Review, “110 Women in Medtech to Know”

Humacyte Founder Laura Niklason, M.D., Ph.D. Recognized on Fortune Magazine’s List of Leaders Transforming Health and Medicine

Dr. Niklason was recognized to Fortune Magazine’s prestigious List of Leaders Transforming Health and Medicine, for her contributions to the advancement of regenerative medicine, in creating investigational human acellular vessels.

Humacyte Founder Dr. Laura Niklason, M.D., Ph.D. awarded with a 2016 LAS Alumni Achievement Award

Dr. Laura Niklason received a LAS Alumni Achievement Award from the University of Illinois College of Liberal Arts & Sciences for groundbreaking work in tissue engineering in 2016.

Humacyte named 2016 Fierce Innovation Awards finalist

Humacyte was named to Fierce Innovation’s Awards Life Sciences Edition in 2016 for creating HUMACYL

Humacyte named to FierceBiotech’s Top 15 Private Companies in the Medical Devices Space for 2016

Humacyte was named to FierceBiotech’s Top 15 Private Companies in Medical Devices for the potential to significantly impact business and society through new technologies in regenerative medicine.

WSJ Includes Humacyl as one of “Six New Medical Technologies Worth Watching”

Humacyte was highlighted as a potential breakthrough for patients undergoing hemodialysis.

Humacyte makes CNBC Disruptor 50 List

Humacyte was named to CNBC’s prestigious Disrupt 50 List for the progress HUMACYL has made since Humacyte’s founding.

Humacyte Chief Medical Officer Jeffrey H. Lawson M.D., Ph.D. Elected to Fellowship in the American Surgical Association

Humacyte’s Chief Medical Officer, Dr. Jeffery H. Lawson was elected as a Fellow to the prominent American Surgical Association for his experience and leadership as a medical professional.

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Medicine

Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies and Founder of Humacyte, has been elected to the prestigious National Academy of Medicine (NAM). NAM is an independent organization of eminent professionals from diverse fields including health and medicine; the natural, social, and behavioral sciences, and beyond.

North Carolina Excellence Award

Humacyte, an innovator in biotechnology and regenerative medicine, announced today that the Company has been awarded the 2015 North Carolina Excellence Award by the US Commerce & Trade Research Institute (USCTRI), a leading research authority that evaluates and recognizes businesses and organizations that have made a significant contribution in enterprise and entrepreneurial growth.

Excellence in Commerce Award

The Small Business Institute for Excellence in Commerce (SBIEC) recognizes Humacyte with the 2013 North Carolina Excellence Award for continued advancement of business leadership and high regard for upholding business ethics and company values among its peers.

Top 10 Women in Biotech

Fierce Biotech names Carrie Cox as one of the “Top 10 Women in Biotech”

Fast Company Top 50 World’s Most Innovative Companies

Fast Company names Humacyte as one of the “Top 50 World’s Most Innovative Companies”

Popular Mechanics Breakthrough Innovation of 2011

Popular Mechanics recognizes Humacyte investigational bioengineered blood vessel technology as a “Breakthrough Innovation of 2011.” This technology is under clinical study by Humacyte, and Humacyte plans to seek FDA approval of the technology.

Frost & Sullivan New Product Innovation

Humacyte receives Frost & Sullivan Award for New Product Innovation

In The Spotlight

Awards & Acknowledgments

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

Vermont Distinguished Academic Achievement Award

Diversity Journal Women Worth Watching

Triangle Business Journal Life Sciences Awards

Triangle Business Journal

Triangle Business Journal 2018 Innovation Awards

Humacyte was named as a finalist in the Strategic Investment Category to the SEBIO 2018 Awards List

Triangle Business Journal 2018 C-Suite Awards List

Diversity Journal Women’s Worth Watching

Humacyte Founder Shannon Dahl’s, Ph.D. Named to the 2018 PharmaVoice100 List Awards Finalist

Humacyte’s Theodore Lithgow, Chief Operations Officer, was recognized in the 2017 Best in Biz awards under the Executive of the Year

Medical Design & Outsourcing: Humacyte’s Carrie Cox named to 9 Women Medtech Leaders You Need to Know list

Humacyte Founder Laura Niklason, M.D., Ph.D. Named to the 2017 PharmaVoice100 List Awards Finalist

Humacyte Founder Laura Niklason, M.D., Ph.D. Inducted into the Women in Technology (WITI) Hall of Fame

Humacyte’s Heather Prichard, Ph.D., named as a 2017 award winner for Diversity Journal’s Women Worth Watching in STEM

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

Humacyte’s Juliana Blum and Jenny Jackson Named to Profiles in Diversity Journal’s 2017 Women Worth Watching List

Humacyte Founder Dr. Laura Niklason and Humacyte CEO Carrie Cox Named to Becker’s Hospital Review List of 110 Women in Medtech to Know

Humacyte Founder Laura Niklason, M.D., Ph.D. Recognized on Fortune Magazine’s List of Leaders Transforming Health and Medicine

Humacyte Founder Dr. Laura Niklason, M.D., Ph.D. awarded with a 2016 LAS Alumni Achievement Award

Humacyte named 2016 Fierce Innovation Awards finalist

Humacyte named to FierceBiotech’s Top 15 Private Companies in the Medical Devices Space for 2016

WSJ Includes Humacyl as one of “Six New Medical Technologies Worth Watching”

Humacyte makes CNBC Disruptor 50 List

Humacyte Chief Medical Officer Jeffrey H. Lawson M.D., Ph.D. Elected to Fellowship in the American Surgical Association

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Medicine

North Carolina Excellence Award

Excellence in Commerce Award

Top 10 Women in Biotech

Fast Company Top 50 World’s Most Innovative Companies

Popular Mechanics Breakthrough Innovation of 2011

Frost & Sullivan New Product Innovation

Coming to a city near you.